skip to Main Content

Expert Highlights Ongoing Research and Challenges in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Beyond agents such as gemcitabine, nab-paclitaxel (Abraxane), and FOLFIRINOX available in the pancreatic cancer paradigm, Ramesh K. Ramanathan, MD, explained that there are a number of other strategies under investigation.

One agent being explored is pegylated hyaluronidase (PEGPH20), which has also received much attention. A pilot study with PEGPH20 plus gemcitabine/nab-paclitaxel (Abraxane) showed potential for patients with high levels of hyaluronan (HA) and is now in a phase III study (NCT02715804). Read more . . . 

Back To Top